0 Ratings
ID

12574

Description

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01804101

Link

https://clinicaltrials.gov/show/NCT01804101

Keywords

Versions (1)
  1. 2/12/15 2/12/15 -
Uploaded on

2 de diciembre de 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    English

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    1 forms  
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693 (Inclusion)
    Diagnosis of untreated high-risk myelodysplastic syndrome (>= 10% blasts) or aml
    Description

    other than acute promyelocytic leukemia (apl) with t(15;17)(q22;q12) or variants according to the 2008 world health organization (who) classification; patients with biphenotypic aml are eligible; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution and cytogenetic/molecular information is available

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C3463824 (MYELODYSPLASTIC SYNDROME)
    SNOMED
    109995007
    UMLS CUI [2]
    C0026998 (Acute Myeloid Leukemia, M1)
    SNOMED
    103690005
    prior hydroxyurea for aml is permitted but should be discontinued prior to start of cpx-351 treatment
    Description

    prior hydroxyurea for aml

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0020402 (hydroxyurea)
    SNOMED
    56602009
    UMLS CUI [2]
    C0521104 (permission)
    SNOMED
    75554001
    UMLS CUI [3]
    C1706472 (Discontinue - dosing instruction imperative)
    SNOMED
    421286000
    azacitidine, decitabine, lenalidomide, and growth factors are permitted for low-risk mds (< 10% blasts); all treatments for mds should be discontinued prior to start of cpx-351 treatment
    Description

    discontinue treatment for myelodysplastic syndrome

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0584668 (Recommendation to stop drug treatment)
    SNOMED
    304540007
    treatment-related mortality (trm) score >= 13.1 as calculated with simplified model
    Description

    treatment-related mortality score

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0457450 (Mortality prediction model score)
    SNOMED
    278303002
    bilirubin < 2.0 mg/ml x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    Description

    Liver function

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0232741 (Liver function)
    SNOMED
    79036002
    LOINC
    LP31397-0
    aspartate aminotransferase (ast)/alanine aminotransferase (alt) < 4.0 x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    Description

    Liver function

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0232741 (Liver function)
    SNOMED
    79036002
    LOINC
    LP31397-0
    left ventricular ejection fraction (lvef) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (muga) scan or echocardiography, or other appropriate diagnostic modality
    Description

    left ventricular ejection fraction

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0428772 (Left ventricular ejection fraction)
    SNOMED
    250908004
    patients with symptoms/signs of hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    Description

    hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C3805210 (Hyperleukocytic syndrome)
    UMLS CUI [2]
    C0023416 (Leukapheresis)
    SNOMED
    77257005
    provide signed written informed consent
    Description

    informed consent

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0021430 (Informed Consent)
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251 (Exclusion Criteria)
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    Description

    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C2861579 (Chronic myelogenous leukemia with crisis of blast cells)
    UMLS CUI [2]
    C0205269 (Unresponsive to Treatment)
    SNOMED
    20646008
    concomitant illness associated with a likely survival of < 1 year
    Description

    Comorbidity with a likely survival of < 1 year

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0009488 (Comorbidity)
    UMLS CUI [2]
    C2919552 (Survival time)
    SNOMED
    445320007
    active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
    Description

    infection, unless under treatment

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0009450 (Communicable Diseases)
    SNOMED
    189822004
    UMLS CUI [2]
    C0087111 (Therapeutic procedure)
    SNOMED
    277132007
    LOINC
    LP21090-3
    Back to the top of the page

    Similar models

    Eligibility Acute Biphenotypic Leukemia NCT01804101

    1 forms
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    untreated high-risk myelodysplastic syndrome or aml
    Item
    Diagnosis of untreated high-risk myelodysplastic syndrome (>= 10% blasts) or aml
    boolean
    C3463824 (UMLS CUI [1])
    C0026998 (UMLS CUI [2])
    prior hydroxyurea for aml
    Item
    prior hydroxyurea for aml is permitted but should be discontinued prior to start of cpx-351 treatment
    boolean
    C0020402 (UMLS CUI [1])
    C0521104 (UMLS CUI [2])
    C1706472 (UMLS CUI [3])
    discontinue treatment for myelodysplastic syndrome
    Item
    azacitidine, decitabine, lenalidomide, and growth factors are permitted for low-risk mds (< 10% blasts); all treatments for mds should be discontinued prior to start of cpx-351 treatment
    boolean
    C0584668 (UMLS CUI [1])
    treatment-related mortality score
    Item
    treatment-related mortality (trm) score >= 13.1 as calculated with simplified model
    boolean
    C0457450 (UMLS CUI [1])
    Liver function
    Item
    bilirubin < 2.0 mg/ml x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    boolean
    C0232741 (UMLS CUI [1])
    Liver function
    Item
    aspartate aminotransferase (ast)/alanine aminotransferase (alt) < 4.0 x upper limit of normal; this requirement reflects the excretion of cpx-351 by the liver
    boolean
    C0232741 (UMLS CUI [1])
    left ventricular ejection fraction
    Item
    left ventricular ejection fraction (lvef) >= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition (muga) scan or echocardiography, or other appropriate diagnostic modality
    boolean
    C0428772 (UMLS CUI [1])
    hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    Item
    patients with symptoms/signs of hyperleukocytosis or white blood cell count (wbc) > 100,000/ul can be treated with leukapheresis prior to enrollment
    boolean
    C3805210 (UMLS CUI [1])
    C0023416 (UMLS CUI [2])
    informed consent
    Item
    provide signed written informed consent
    boolean
    C0021430 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    Item
    refractory/relapsing blast crisis of chronic myelogenous leukemia (cml)
    boolean
    C2861579 (UMLS CUI [1])
    C0205269 (UMLS CUI [2])
    Comorbidity with a likely survival of < 1 year
    Item
    concomitant illness associated with a likely survival of < 1 year
    boolean
    C0009488 (UMLS CUI [1])
    C2919552 (UMLS CUI [2])
    infection, unless under treatment
    Item
    active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
    boolean
    C0009450 (UMLS CUI [1])
    C0087111 (UMLS CUI [2])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial